StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Xeris Biopharma's operating income for the twelve months ending Jun 30, 2026 was $36.59M. For fiscal 2025 it was $24.90M. The highest annual figure on record is $24.90M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$24.90M–
FY2024Dec 31, 2024-$33.65M–
FY2023Dec 31, 2023-$44.01M–
FY2022Dec 31, 2022-$81.94M–
FY2021Dec 31, 2021-$115.16M–
FY2020Dec 31, 2020-$83.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.17M+15.4%
Q1 FY2026Mar 31, 2026$7.92M–
Q4 FY2025Dec 31, 2025$16.77M+899.0%
Q3 FY2025Sep 30, 2025$6.73M–
Q2 FY2025Jun 30, 2025$4.48M–
Q1 FY2025Mar 31, 2025-$3.09M–
Q4 FY2024Dec 31, 2024$1.68M–
Q3 FY2024Sep 30, 2024-$12.89M–
Q2 FY2024Jun 30, 2024-$8.19M–
Q1 FY2024Mar 31, 2024-$14.25M–
Q4 FY2023Dec 31, 2023-$9.84M–
Q3 FY2023Sep 30, 2023-$4.91M–
Q2 FY2023Jun 30, 2023-$15.98M–
Q1 FY2023Mar 31, 2023-$13.28M–
Q4 FY2022Dec 31, 2022-$15.17M–
Q3 FY2022Sep 30, 2022-$18.78M–
Q2 FY2022Jun 30, 2022-$18.92M–
Q1 FY2022Mar 31, 2022-$29.07M–
Q4 FY2021Dec 31, 2021-$48.27M–
Q3 FY2021Sep 30, 2021-$24.36M–
Q2 FY2021Jun 30, 2021-$25.79M–
Q1 FY2021Mar 31, 2021-$16.74M–
Q4 FY2020Dec 31, 2020-$19.34M–
Q3 FY2020Sep 30, 2020-$13.74M–

More Xeris Biopharma figures

See a number that looks wrong?